On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI).
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ® and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ® platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery™ to improve the care of patients receiving radiation therapy.
A variety of courses and resources are available for physicians to help guide patients with a cancer diagnosis through fertility preservation issues, a topic not often addressed soon enough with female and male patients between the ages of 15 and 39.
The National Cancer Institute (NCI) has identified and posted more than a dozen funding announcements (FOAs) that align with the goals of the Cancer Moonshot Initiative.
A new ASCO Special Article in the Journal of Oncology Practice (JOP) highlights of a joint National Institute for Occupational Safety and Health (NIOSH) and ASCO workshop on the Safe Handling of Hazardous Drugs.
On Feb. 15, 2017, ASCO leadership and members of the ASCO Government Relations Committee (GRC) met with key federal agency and congressional committee staff to discuss ASCO's top policy priorities. Discussions focused on federal efforts to repeal and replace the Affordable Care Act (ACA), implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) and the 21st Century Cures Act, among other matters.
The deadline to submit reconsideration applications for the 2017 Electronic Health Record (EHR) Incentive Program payment adjustment—based on the 2015 reporting period—is Feb. 28, 2017. Applications will not be accepted after the deadline.
Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network® (NCCN®) announce a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy.
Last week, ASCO submitted joint comment letters with the State Affiliates in Connecticut and Washington in support of legislation that would increase the legal age for the purchase of tobacco products to 21. ASCO is committed to policies that will contribute to reducing prevalence of tobacco use to ultimately prevent the occurrence of cancer and other smoking-caused diseases.
A new program offers health and wellness options for people living with cancer through their local YMCA. LIVESTRONG® at the YMCA is an evidence-based wellness and exercise program that helps adult cancer survivors reclaim their health and well-being following a cancer diagnosis.
ASCO endorsed the bipartisan Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act (H.R. 820/S.292), which would help accelerate research for pediatric cancer and improve care for the 15,780 children diagnosed with cancer in the U.S. every year.
The Journal of Oncology Practice’s (JOP) is expanding its diverse content on the day-to-day practice of oncology to include Care Delivery Reviews.
“ASCO congratulates Representative Tom Price for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). Secretary Price has a unique opportunity to shape the availability and quality of care for millions of people with cancer and maintain the nation’s leadership in biomedical research.
ASCO joined a letter from the Ad Hoc Group for Medical Research urging Congress and the Administration to enact a final fiscal year (FY) 2017 spending bill that includes $34.1 billion for the National Institutes of Health (NIH). The letter also asks Congress and the Administration to make the NIH a priority as they consider funding for FY 2018.